Abstract
This paper discusses the use made of the antigenic specificity of malignant tumours in the diagnosis and subsequent management of a patient with secondary malignant disease who had previously been treated for both carcinoma of the breast and malignant melanoma. A comparatively simple, rapid test (leucocyte adherence inhibition) was used to determine the patient's antitumour immunoreactivity. Cell-mediated immunity against both types of tumour was detected, but this was accompanied by serum-blocking factor corresponding to melanoma only, which indicated that the secondary malignant disease was melanoma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
